An excellent year of growth in 2011

01/26/2012

Annual sales objective achieved
+12.3% organic growth at constant scope and currency

Avignon, 25 January 2012 - NATUREX, NATUREX, world leader in specialty plant-based ingredients, presents its annual consolidated sales the year 2011:

 

K€
 IFRS
 Unaudited data
2011 2010 Var. % Var. %
 at constant currency
1st quarter 64,021 51,611 +24.0% +17.5%
2nd quarter 63,904 60,478 +5.7% +9.3%
3rd quarter 63,226 58,472 +8.1% +12.0%
4th quarter (excluding BURGUNDY) 59,718 55,746 +7.1% +11.1%
Annual sales
 Constant scope
250,869 226,307 +10.9% +12.3%
Integration of BURGUNDY 2,700 - -  
4th quarter (new scope) 62,418 55,746 +12.0%  
Annual sales
 New scope
253,568 226,307 +12.0%  

2011 was a further year of strong growth for NATUREX, which recorded excellent levels of activity over all markets and in all geographic areas where the Group is established.
In October 2011, NATUREX performed the acquisition of BURGUNDY, specialised in the production and marketing of plant extracts for the nutraceutical, pharmaceutical and cosmetics industries, which sales have been consolidated from 1st October 2011.
Thus the sales generated over the year 2011 amounted to 253.6 million euros, an increase of 12.0%.  At constant scope and exchange rate, the growth in sales was 12.3%, in compliance with the published annual growth objective.
The activity of the 4th quarter of 2011 was in the same growth dynamic as the previous quarters and the integration of the activities of BURGUNDY within NATUREX generated additional revenue of 2.7 million euros. The sales for the 4th quarter of 2011 thus amounted to 62.4 million euros, up 12.0%.

Strong growth of the three markets around a widened product range

 
 

K€
IFRS
Unaudited data
2011* 2010 Share of turnover
%
Var.
%
Food & Beverage 153,412 137,108 60.5% +11.9%
Nutrition & Health 84,496 75,523 33.3% +11.9%
Personal Care 3,008 2,709 1.2% +11.0%
Miscellaneous
and toll extraction
12,652 10,967 5.0% +15.4%

* New scope: Integration of the turnover of BURGUNDY over the 4th quarter 2011

Growth was good in the different markets, the integration of the activities of BURGUNDY enabled to complete the offer in the fields of Nutrition & Health and Personal Care.
 

Dynamism of all geographic areas

K€
 IFRS
 Unaudited data
2011* 2010 Share of turnover
 %
Var.
 %
Europe / Africa 132,013 117,718 52.1% +12.1%
Americas 92,708   84,107 36.6% +10.2%
Asia / Oceania 28,847 24,482 11.4% +17.8%

* New scope: Integration of the turnover of BURGUNDY over the 4th quarter 2011
With commercial coverage widened to 18 locations, including 3 openings of commercial offices over the year, NATUREX has not only strengthened its positions worldwide, but has also created real proximity with local and regional customers, enabling it to catch the growth of both mature markets and emerging markets:

The emerging markets of Eastern Europe, Asia, Latin America, Africa and the Middle East which represented 14% of the Group’s sales over 2011, compared with less than 10% one year previously, offer highly promising development prospects.
“We are very satisfied with this excellent year of growth, marked by the positive orientation of all of our activities and geographic zones.  The integration of BURGUNDY is now on the road to completion and our teams are working actively to quickly develop the commercial synergies.” declared Jacques Dikansky, Chief Executive Officer and Founder of NATUREX.
“With our strengthened geographic positioning, the highly favourable acceptance of our new product ranges and our industrial and scientific expertise, we are confident in our ability to continue to outperform the future growth of our markets.”
 
Next publications
-    Annual results 2011    28 March 2012

Forthcoming events
-    Midcap Event Brussels    29-30 March 2012
-    SFAF analysts meeting - Paris    2 April 2012
 
Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps).
Number of shares comprising the capital: 7,705,580
6,718,272 ordinary shares (ISIN FR0000054694)
987,308 preferred shares (ISIN FR0010833251)
Naturex is a component of the CAC Small and Gaïa indexes.
Naturex is eligible for "long only" Deferred Settlement Service (SRD).
Naturex has implemented a Sponsored Level I American Depositary Receipt (ADR) program,
which trades on over-the-counter market in the United States under symbol NTUXY.
TICKER: NRX - Reuters : NATU.PA - Bloomberg : NRX:FP - DR Symbol: NTUXY
About Naturex
NATUREX is a global leader in specialty plant-based natural ingredients.
The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
NATUREX’s head office is based in Avignon, France. The company employs more than 1,000 people with high-performance manufacturing operations across 13 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland), as well as in Morocco, the United States, Brazil and Australia. It also has a global presence through a dedicated network of sales offices in 18 countries (France, Italy, Spain, the United Kingdom, Belgium, Germany, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil and Mexico).
NATUREX's development is supported by positive underlying trends linked to a fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.

Contacts

Jacques Dikansky

President and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89

naturex@naturex.com

 

Thierry Lambert

Vice-President and Chief Financial Officer

Tel.: +33 (0)4 90 23 96 89

t.lambert@naturex.com

 

Carole Alexandre

Investor Relations

Tel.: +33 (0)4 90 23 78 28

c.alexandre@naturex.com

 

Anne Catherine Bonjour

Actus Finance Press Relations

Tel.: +33 (0)1 53 67 36 93

acbonjour@actus.fr

actu_113_Fichierpdf.pdf
 
of 228
BACK